S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:BNOX

Bionomics - BNOX Stock Forecast, Price & News

$4.28
-0.12 (-2.73%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.02
▼
$5.33
50-Day Range
$3.80
▼
$7.24
52-Week Range
$3.51
▼
$12.99
Volume
40,453 shs
Average Volume
10,605 shs
Market Capitalization
$34.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Bionomics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
239.2% Upside
$14.50 Price Target
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Bionomics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.54) to ($3.48) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

837th out of 1,049 stocks

Pharmaceutical Preparations Industry

409th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

BNOX stock logo

About Bionomics (NASDAQ:BNOX) Stock

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

BNOX Stock News Headlines

January 20, 2023 | americanbankingnews.com
Bionomics Limited (NASDAQ:BNOX) Short Interest Up 150.0% in December
December 21, 2022 | finanznachrichten.de
Bionomics Ltd: Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
January 29, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 19, 2022 | finance.yahoo.com
Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint
December 19, 2022 | markets.businessinsider.com
Bionomics' BNC210 Phase 2 Study In Social Anxiety Disorder Fails To Meet Primary Goal
December 2, 2022 | finance.yahoo.com
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
November 17, 2022 | finanznachrichten.de
Bionomics Ltd: Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
November 2, 2022 | finance.yahoo.com
Bionomics Limited to Participate in Upcoming November Investor Conferences
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
October 25, 2022 | reuters.com
BNOX.OQ - | Stock Price & Latest News | Reuters
October 5, 2022 | barrons.com
Bionomics Ltd. ADR
October 1, 2022 | cnbc.com
Squawk Box
September 15, 2022 | finance.yahoo.com
Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect?
August 31, 2022 | finance.yahoo.com
Bionomics to Participate in Upcoming September Investor Conferences
August 8, 2022 | finance.yahoo.com
Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M
July 29, 2022 | finance.yahoo.com
Quarterly Activities Report for June 2022
July 8, 2022 | benzinga.com
Bionomics to Participate in William Blair's Biotech Focus Conference 2022
June 27, 2022 | finance.yahoo.com
Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference
May 11, 2022 | markets.businessinsider.com
Novamind And Numinus Prepare For Acquisition, Both Companies Share Info Circulars To Shareholders
May 10, 2022 | finanznachrichten.de
Novamind Inc.: Novamind to Host Bionomics' PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
March 30, 2022 | benzinga.com
6 Stocks Halted In Wednesday's Session
February 25, 2022 | investing.com
Bionomics Ltd ADR (BNOX)
January 15, 2022 | nasdaq.com
Bionomics Limited Rings the Nasdaq Stock Market Closing Bell
January 14, 2022 | nasdaq.com
Bionomics Limited Rings the Closing Bell
January 13, 2022 | reuters.com
BNOX.OQ - Bionomics Ltd Profile | Reuters
January 12, 2022 | finance.yahoo.com
Bionomics Limited participated in the H.C Wainwright BioConnect Conference
January 5, 2022 | finance.yahoo.com
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States
See More Headlines
Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

BNOX Company Calendar

Today
1/29/2023
Fiscal Year End
6/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNOX
CUSIP
N/A
CIK
1191070
Web
www.bionomics.com.au
Phone
61 8 8354 6100
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.50
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+239.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
12.46
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$260,000.00
Price / Sales
134.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.38 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
8,160,000
Free Float
8,038,000
Market Cap
$34.88 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Adrian Hinton BEC (Age 71)
    F.C.A., Acting Chief Financial Officer
    Comp: $223.12k
  • Mr. Connor Bernstein M.Sc. (Age 35)
    VP of Strategy & Corp. Devel.
    Comp: $237.72k
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
  • Ms. Suzanne Irwin B.Com.
    FCIS, Company Sec.

Key Competitors

View All Competitors













BNOX Stock - Frequently Asked Questions

Should I buy or sell Bionomics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNOX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNOX, but not buy additional shares or sell existing shares.
View BNOX analyst ratings or view top-rated stocks.

What is Bionomics' stock price forecast for 2023?

3 equities research analysts have issued 1 year target prices for Bionomics' shares. Their BNOX share price forecasts range from $6.00 to $23.00. On average, they predict the company's share price to reach $14.50 in the next year. This suggests a possible upside of 239.2% from the stock's current price.
View analysts price targets for BNOX or view top-rated stocks among Wall Street analysts.

How have BNOX shares performed in 2023?

Bionomics' stock was trading at $4.65 at the start of the year. Since then, BNOX shares have decreased by 8.1% and is now trading at $4.2750.
View the best growth stocks for 2023 here.

When did Bionomics IPO?

(BNOX) raised $20 million in an initial public offering on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share.

What is Bionomics' stock symbol?

Bionomics trades on the NASDAQ under the ticker symbol "BNOX."

How do I buy shares of Bionomics?

Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionomics' stock price today?

One share of BNOX stock can currently be purchased for approximately $4.28.

How much money does Bionomics make?

Bionomics (NASDAQ:BNOX) has a market capitalization of $34.88 million and generates $260,000.00 in revenue each year.

How can I contact Bionomics?

Bionomics' mailing address is 31 Dalgleish St, Thebarton, South Australia 5031. The official website for the company is www.bionomics.com.au. The company can be reached via phone at 61 8 8354 6100 or via email at investorrelations@bionomics.com.

This page (NASDAQ:BNOX) was last updated on 1/29/2023 by MarketBeat.com Staff